Clinical guidelines recommend annual screening for chlamydia trachomatis for women under age 25, but a new report concludes screening for all women between the ages of 15 and 29 is cost-effective. Researchers compared the cost-effectiveness of four scenarios, ranging from no screening to annual screening followed by selective semi-annual screening in women with a prior infection, and found the latter option was most cost-effective.

Related Summaries